The study evaluates the effects of genistein on blood pressure (BP) and ultrastructural changes in kidney of fructose-fed hypertensive rats. Male Wistar rats were fed a diet containing 60% starch or 60% fructose as the source of carbohydrate. After 15 d, rats in each dietary group were divided into two groups and were treated with either genistein (1 mg/kg per d) in dimethylsulfoxide (DMSO) or 30% DMSO alone. BP, pressor mechanisms, protein kinase C-\(\beta\)II (PKC-\(\beta\)II) expression, endothelial NO synthase (eNOS) expression and renal ultrastructural changes were evaluated after 60 d. Fructose-fed rats displayed significant elevation in BP and heart rate. Significant increase in plasma angiotensin-converting enzyme (ACE) activity, alterations in renal lipid profile, nitrite and kallikrein activity, enhanced expression of membrane-associated PKC-\(\beta\)II and decreased expression of eNOS were observed in them. Histology and electron microscopic studies showed structural changes in the kidney. Genistein administration lowered BP, restored ACE, PKC-\(\beta\)II and eNOS expression and preserved renal ultrastructural integrity. These findings demonstrate that genistein has effects on eNOS activity in renal cells, leading to eNOS activation and NO synthesis. These effects could have been mediated by activation of PKC-\(\beta\)II. The observed benefits of genistein make it a promising candidate for therapy of diabetic kidney disease.

Key words: Blood pressure; Endothelial nitric oxide synthase; Fructose; Genistein; Nitric oxide
Adult male Wistar rats of body weight 150–160 g were obtained from the Central Animal House, Rajah Muthiah Medical College and Hospital (RMMCH), Annamalai University. They were housed in a well-ventilated animal room under controlled conditions on a 12 h light–12 h dark cycle. Animals received the standard pellet diet (Karnataka State Agro Corporation Limited, Agro Feeds Division) and water ad libitum. The experimental procedures were done according to the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals and were approved by the Institutional Ethical Committee of Animal Care, RMMCH, Annamalai University, Annamalai Nagar, India (no. 160/1999/CPCSEA/425).

Experimental design

After the acclimatisation period of 7 d, the rats were divided into four groups of twelve rats each as follows: (1) Group 1 rats were fed the control diet containing 60% maize starch, 20% protein, 0·7% methionine, 5% ground nut oil, 10·6% wheat bran, 3·5% salt mixture and 0·2% vitamin mixture and received the vehicle (0·5 ml 30% dimethylsulfoxide/d) by oral administration for 60 d, (2) Group 2 rats were fed the high-fructose diet, which had similar composition to that of the control diet, except that starch was replaced by fructose, and administered dimethylsulfoxide for 60 d, as described for rats in Group 1; (3) Group 3 rats were fed the high-fructose diet and administered genistein (1 mg/kg per d in 0·5 ml dimethylsulfoxide) from day 16 until day 60 by oral administration and (4) Group 4 rats were fed the control diet and administered genistein from the 16th day till the 60th day of the experimental period, as described for Group 3.

On day 60, the animals (n 6) were kept in individual metabolism cages, and 24 h urine samples were collected in sealed beakers with added preservative and killed by cervical dislocation after administering anaesthesia (ketamine hydrochloride 30 mg/kg, intramuscular). The abdomen was cut open and kidneys were dissected, washed in ice-cold saline and weighed. Portions of kidney were cut and homogenised in 0·1 M Tris–HCl buffer (pH 7·4) and used for the assays.

Blood pressure measurement

BP was measured in conscious rats (n 6) by the indirect tail-cuff method using a fully automatic BP analyser (Doc-NIBP200A, BIO PAC Systems). The rats were kept in a constant temperature (32°C) chamber for 30 min and then placed in a rat holder. A total of eight BP measurements were carried out in each animal. An average of six such readings was taken as the individual (systolic/diastolic) BP, neglecting the maximal and minimal values. The sum of the diastolic pressure and one-third of the pulse pressure was taken as the mean arterial pressure.

Biochemical analysis

Total nitrite (nitrate + nitrite) as a measure of NO\textsuperscript{(39)}, plasma ACE activity\textsuperscript{(10)} and the activity of kallikrein\textsuperscript{(11)} were measured. Plasma and renal tissue cholesterol, TAG and NEFA were measured by methods outlined elsewhere\textsuperscript{(12)}.

Immunoblot analysis of protein kinase C-βII and endothelial nitric oxide synthase

The cytosol and membrane fractions of the kidney were prepared as follows: 500 mg of kidney were homogenised in 5 ml of ice-cold extraction buffer (40 mm-sucrose, 50 mm-HEPES, 280 mm-NaCl and 20 mm-NaOH and protease inhibitor cocktail; Sigma Chemical Company). The homogenate was centrifuged at 1000 g for 5 min at 4°C. The supernatant obtained was used as the total cell lysate fraction. The total cell lysate was centrifuged again at 100 000 g for 60 min at 4°C. The supernatant obtained was used as the cytosolic fraction, while the pellet was resuspended in ice-cold lysis buffer (50 mm-HEPES, 480 mm-NaCl, 20 mm-NaOH and 2% SDS) with protease inhibitor cocktail and centrifuged at 100 000 g for 60 min at 4°C. The pellet was discarded and the supernatant was used as the membrane fraction. Protein concentration was measured by the method of Lowry et al\textsuperscript{(13)}. The sample (100 µg protein) was solubilised in 2X Laemmli sample buffer. The total cell lysate (for eNOS expression) and the cytoplasmic and membrane proteins (for PKC-βII expression) were subjected to electrophoresis in SDS-PAGE gel (6% for eNOS and 8% for PKC-βII) and blotted onto nitrocellulose membranes in a transferring buffer at 80 mA in a transfer apparatus for 1 h and 30 min. The membranes were then pre-incubated in the blocking buffer (PBS containing 0·05% Tween-20 (PBS-T)) and 5% non-fat dried milk for 2 h at room temperature and then probed with rabbit polyclonal anti-eNOS primary antibody (1:750 dilution) or mouse monoclonal anti-PKC-βII primary antibody (1:1000 dilution) overnight at 4°C and washed with PBS-T thrice and incubated with either goat anti-rabbit secondary antibody (1:4000) or goat anti-mouse secondary antibody (1:5000 dilution) (Genei) for 2 h and again washed with PBS-T thrice. Antigen–antibody complexes were detected using a chemiluminescence kit (Thermo Fisher Scientific, Inc.) and quantified by Image J, a public domain Java image processing software (Wayne Rasband, National Institutes of Health). β-Actin was used as the housekeeping internal control. The data for test proteins are normalised with corresponding β-actin values and are presented as arbitrary units.

Histology

A portion of kidney tissue removed from each group was fixed in 8% neutral formalin, dried and embedded in paraffin wax. Sections of 3–5 mm were cut, processed and stained with periodic acid–Schiff stain. The slides were examined under a light microscope.

Transmission electron microscopic examination of kidney

A portion of renal tissue was cut into small pieces and prefixed in 2·5% glutaraldehyde (0·2 mol/l cacodylate buffer,
pH 7.4) for 4 h and then post-fixed in 1% buffered osmium tetroxide for 1 h and embedded in epoxyresin. Ultra-thin sections were stained with uranyl acetate and lead citrate, examined and photographed under a Philips-P201 transmission electron microscope (Koninklijke Philips Electronics).

Statistical analysis

Values are expressed as means and standard deviations. Data within the groups were analysed using one-way ANOVA followed by Duncan’s multiple range test. A value of $P < 0.05$ was considered statistically significant.

Results

Blood pressure, nitrite, kallikrein and angiotensin-converting enzyme

Table 1 presents body and kidney weight, systolic and diastolic blood pressure, mean arterial pressure (MAP), heart rate, angiotensin-converting enzyme (ACE), kallikrein and nitrite in plasma and urine of experimental rats (Mean values and standard deviations of six animals):

<table>
<thead>
<tr>
<th>Parameters</th>
<th>CON</th>
<th>FRU</th>
<th>FRU + GEN</th>
<th>CON + GEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>182.9 ± 12.4</td>
<td>226.6* ± 14.7</td>
<td>189.3† ± 11.9</td>
<td>186.6 ± 11.0</td>
</tr>
<tr>
<td>Kidney weight (g)</td>
<td>1.95 ± 0.13</td>
<td>2.24* ± 0.14</td>
<td>1.75† ± 0.11</td>
<td>1.91 ± 0.11</td>
</tr>
<tr>
<td>Systolic pressure (mmHg)</td>
<td>115.6 ± 8.9</td>
<td>189.2* ± 12.5</td>
<td>128.64† ± 8.12</td>
<td>113.21 ± 8.36</td>
</tr>
<tr>
<td>Diastolic pressure (mmHg)</td>
<td>72.1 ± 5.5</td>
<td>94.9* ± 6.2</td>
<td>79.37† ± 5.01</td>
<td>68.16 ± 5.03</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>86.6 ± 6.7</td>
<td>126.3* ± 8.3</td>
<td>95.79† ± 6.04</td>
<td>83.18 ± 6.14</td>
</tr>
<tr>
<td>Heart rate (beats per min)</td>
<td>343 ± 26.3</td>
<td>379* ± 25</td>
<td>344.51† ± 21.7</td>
<td>342.32 ± 25.29</td>
</tr>
</tbody>
</table>

Plasma

ACE (nkat/l) | 123.50 ± 8.33 | 239.00* ± 14.00 | 141.84† ± 8.83 | 123.00 ± 7.16 |
| Kallikrein (µmol of substrate converted/min per litres of plasma) | 5.27 ± 0.35 | 4.35* ± 0.25 | 6.01† ± 0.37 | 5.29 ± 0.31 |
| Nitrite (µmol/l) | 11.83 ± 0.90 | 8.54* ± 0.56 | 10.0† ± 0.63 | 11.83 ± 0.87 |

Urine

Nitrite (µmol/d per 100 g body weight) | 2.67 ± 0.20 | 1.73* ± 0.11 | 2.30† ± 0.14 | 2.71 ± 0.19 |

CON, control rats; FRU, fructose-fed rats; FRU + GEN, fructose + genistein (1 mg/kg body weight per d); CON + GEN, control + genistein (1 mg/kg body weight per d). * Mean values were significantly different compared to control rats ($P < 0.05$; Duncan’s multiple range test). † Mean values were significantly different compared to fructose-fed rats ($P < 0.05$; Duncan’s multiple range test).

Plasma and kidney lipid content

Fig. 1(a) and (b) represent the levels of plasma and kidney lipids, respectively, in experimental animals. Significant increases were observed in plasma cholesterol, TAG and NEFA in the fructose-fed rats (by 29, 40 and 35%, respectively). Genistein administration resulted in significant reductions in cholesterol, TAG and NEFA levels in fructose-fed rats. Similarly, the levels of cholesterol, NEFA and TAG were significantly higher in the kidney of fructose-fed rats than in those fed the control diet (Fig. 1(b)). Genistein treatment of fructose-fed rats restored the levels of kidney lipids to near-normal values.

Statistical analysis

Values are expressed as means and standard deviations. Data within the groups were analysed using one-way ANOVA followed by Duncan’s multiple range test. A value of $P < 0.05$ was considered statistically significant.

Results

Blood pressure, nitrite, kallikrein and angiotensin-converting enzyme

Table 1 presents body and kidney weight, systolic and diastolic blood pressure, mean arterial pressure (MAP), heart rate, angiotensin-converting enzyme (ACE), kallikrein and nitrite in plasma and urine of experimental rats (Mean values and standard deviations of six animals):

<table>
<thead>
<tr>
<th>Parameters</th>
<th>CON</th>
<th>FRU</th>
<th>FRU + GEN</th>
<th>CON + GEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>182.9 ± 12.4</td>
<td>226.6* ± 14.7</td>
<td>189.3† ± 11.9</td>
<td>186.6 ± 11.0</td>
</tr>
<tr>
<td>Kidney weight (g)</td>
<td>1.95 ± 0.13</td>
<td>2.24* ± 0.14</td>
<td>1.75† ± 0.11</td>
<td>1.91 ± 0.11</td>
</tr>
<tr>
<td>Systolic pressure (mmHg)</td>
<td>115.6 ± 8.9</td>
<td>189.2* ± 12.5</td>
<td>128.64† ± 8.12</td>
<td>113.21 ± 8.36</td>
</tr>
<tr>
<td>Diastolic pressure (mmHg)</td>
<td>72.1 ± 5.5</td>
<td>94.9* ± 6.2</td>
<td>79.37† ± 5.01</td>
<td>68.16 ± 5.03</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>86.6 ± 6.7</td>
<td>126.3* ± 8.3</td>
<td>95.79† ± 6.04</td>
<td>83.18 ± 6.14</td>
</tr>
<tr>
<td>Heart rate (beats per min)</td>
<td>343 ± 26.3</td>
<td>379* ± 25</td>
<td>344.51† ± 21.7</td>
<td>342.32 ± 25.29</td>
</tr>
</tbody>
</table>

Plasma

ACE (nkat/l) | 123.50 ± 8.33 | 239.00* ± 14.00 | 141.84† ± 8.83 | 123.00 ± 7.16 |
| Kallikrein (µmol of substrate converted/min per litres of plasma) | 5.27 ± 0.35 | 4.35* ± 0.25 | 6.01† ± 0.37 | 5.29 ± 0.31 |
| Nitrite (µmol/l) | 11.83 ± 0.90 | 8.54* ± 0.56 | 10.0† ± 0.63 | 11.83 ± 0.87 |

Urine

Nitrite (µmol/d per 100 g body weight) | 2.67 ± 0.20 | 1.73* ± 0.11 | 2.30† ± 0.14 | 2.71 ± 0.19 |

CON, control rats; FRU, fructose-fed rats; FRU + GEN, fructose + genistein (1 mg/kg body weight per d); CON + GEN, control + genistein (1 mg/kg body weight per d). * Mean values were significantly different compared to control rats ($P < 0.05$; Duncan’s multiple range test). † Mean values were significantly different compared to fructose-fed rats ($P < 0.05$; Duncan’s multiple range test).
Structural studies

Fig. 4(a)–(d) represents the kidney sections of animals analysed by periodic acid-Schiff staining (40 × magnification). Under a light microscope, kidneys from fructose-fed animals showed glomerular hypertrophy, glomerular sclerosis and interstitial damage (Fig. 4(b)). Kidney sections from fructose + genistein-treated animals showed reduced pathological changes (Fig. 4(c)) compared to those observed in fructose-treated animals. Kidney sections from the control group and the control group treated with genistein showed normal glomerular and tubular histology (Fig. 4(a) and (d)).

Fig. 5 presents the transmission electron microscopic images showing renal architecture and podocyte foot processes of experimental animals. Podocyte and basement membrane from control (Fig. 5(a)) and control plus genistein (Fig. 5(d))-treated groups show similar architecture. Fructose-fed rat kidney shows extensive disruption of podocytes and effacement. Arrows show basement membrane thickening and the presence of excess matrix proteins (Fig. 5(b)). Treatment with genistein significantly prevented these pathological structural changes (Fig. 5(c)). Podocytes and basement membrane appear normal in genistein-treated control animals.

Discussion

The fructose-fed rat is a well established model of the metabolic syndrome associated with renal dysfunction and hypertension. In the present study, fructose feeding caused deleterious effects on pressure-regulatory mechanisms and kidney structure. Several processes that contribute to a rise in BP such as sympathetic nervous system overactivation,
increased production of vasoconstrictors, defects in NO and increased formation of reactive oxygen species are reported in fructose-fed rats. It has been suggested that elevation of BP in this model is a sequence of hyperinsulinaemia, as insulin induces inappropriate Na retention, activation of the sympathetic nervous system and the renin–angiotensin system (15,16).

ACE catalyses the formation of angiotensin II, the aldosterone-stimulating peptide, from angiotensin I. A previous study has shown that genistein decreased ACE expression dose-dependently in rat aortic endothelial cells via oestrogen receptors (17). The antihypertensive and beneficial cardiovascular effects of genistein have been reported by Montenegro et al. (18). The observed mechanisms were inhibition of plasma ACE, both in vivo and in vitro, reduction in the hypertensive response to angiotensin I and increase in the hypotensive response to bradykinin.

The kallikrein enzyme acts on kininogen substrates to release kinins, which bind to the bradykinin B2 receptors, and cause vasodilatation by NO production. Defects in vasodilatory mechanism in fructose-fed rats have been found to be associated with decreased NO production (19) and infusion of sodium nitroprusside, an NO donor, improves insulin sensitivity in fructose-fed rats (20). Vascular protective effects and regulation of eNOS by genistein have been observed in animal and human studies (21,22). Genistein enhances eNOS gene transcription and protein synthesis in spontaneously hypertensive rats (23). Stimulation of NO release and reduction in peripheral vascular resistance by genistein could influence BP and the distribution of blood flow in this model.

Several studies reveal that insulin could regulate the expression of eNOS gene through activation of phosphatidylinositol 3 kinase (PI3) kinase (24). We earlier showed that genistein promotes insulin action in high fructose-fed rats by assessing the homeostasis model assessment values (control rats, 9·39; fructose-fed rats, 42·89; fructose + genistein (1mg/kg body weight per d), 11·16; control + genistein (1mg/kg body weight per d), 8·87), although we did not measure PI3 kinase activation by genistein. Although genistein is a known tyrosine kinase inhibitor, studies have shown that at physiological (low dose) concentration, it induces tyrosine phosphorylation of insulin-like growth factor 1 receptor and insulin receptor substrate-1 in cancer cell lines (25). We suggest that genistein by its insulin sensitivity effects might activate eNOS expression partly via the activation of PI3 kinase.

Podocytes are visceral epithelial cells that share the characteristics of both a mesenchymal and an epithelial cell. The podocyte slit diaphragm is the final filtration barrier in the glomerular endothelial basement membrane–podocyte interface. Podocytopathy is present early in the natural history of diabetic nephropathy and plays an important role in micro- and macro-albuminuria. Broadening of foot processes with eventual effacement and dysfunction of podocytes were observed in fructose-fed rats. In addition, podocyte abnormalities were mitigated by genistein treatment.

Fig. 4. Representative micrographs of kidney tissue stained with periodic acid–Schiff from (a) control rats, (b) fructose-fed rats, (c) fructose + genistein-treated rats (1 mg/kg body weight per d) and (d) control + genistein-treated rats (1 mg/kg body weight per d). (a–d) Magnification 400 ×. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn).
and enhanced ACE activity in the present study. Lowering of glucose and inhibition of ACE by genistein could have contributed to the reduction in PKC-βII activation and BP. The BP-lowering effect of genistein has been shown already in stroke-prone spontaneously hypertensive rats (32), ovariectomised hypertensive rats (33), and in spontaneously hypertensive rats (34). Important vascular effects of genistein include an increase in inducible NO synthase activity, inhibition of platelet aggregation and arterial vasorelaxation (35) and prevention of vascular alterations (36).

In conclusion, the inhibitory effect on ACE and PKC-βII activation and increased availability of kinins and NO could be the contributory mechanism for the BP-lowering effect and renoprotection by genistein. It remains to be seen whether the insulin sensitivity effect of genistein may underlie the renoprotective action.

A large body of evidence has demonstrated that oxidative stress is an important mediator of fructose-induced membrane and structural damage of kidney (26). Genistein might have recovered the kidney from structural alterations by its antioxidative capacity. This has been reported earlier by us using haematoxylin and eosin staining (8). Periodic acid–Schiff staining not only shows glycogen content, but also detects structural deterioration characterised by disorganisation of contractile and cytoskeletal proteins. Genistein was found to improve the overall renal structure.

Elevated circulating lipids may contribute to renal disease progression (27). In contention with this, we observed marked increases in lipid levels in both plasma and kidney of fructose-fed rats. Lipids bind to extracellular matrix molecules and are peroxidised, thereby increasing reactive oxygen species production (28). These processes affect the structure and function of the kidney. Genistein has been shown to be a PPARγ agonist to improve lipid metabolism in murine RAW 264.7 cells and in obese Zucker rats (29). The lipid-lowering effect of genistein observed in the present study could be one of the mechanisms for its renoprotective action.

Hyperglycaemia and angiotensin II are potent inducers of PKC-βII activation (30). Activated PKC-βII translocates to the membrane and triggers the production of endothelin 1, a vasoactive peptide that causes endothelial dysfunction, vascular smooth muscle contraction and proliferation, leading to a rise in BP (31). Fructose-fed rats exhibited hyperglycaemia

References

4. Rajasekar P, Palanisamy N & Anuradha CV (2007) Increase of glucose and inhibition of ACE by genistein could have contributed to the reduction in PKC-βII activation and BP. The BP-lowering effect of genistein has been shown already in stroke-prone spontaneously hypertensive rats (32), ovariectomised hypertensive rats (33), and in spontaneously hypertensive rats (34). Important vascular effects of genistein include an increase in inducible NO synthase activity, inhibition of platelet aggregation and arterial vasorelaxation (35) and prevention of vascular alterations (36).

In conclusion, the inhibitory effect on ACE and PKC-βII activation and increased availability of kinins and NO could be the contributory mechanism for the BP-lowering effect and renoprotection by genistein. It remains to be seen whether the insulin sensitivity effect of genistein may underlie the renoprotective action.

A large body of evidence has demonstrated that oxidative stress is an important mediator of fructose-induced membrane and structural damage of kidney (26). Genistein might have recovered the kidney from structural alterations by its antioxidative capacity. This has been reported earlier by us using haematoxylin and eosin staining (8). Periodic acid–Schiff staining not only shows glycogen content, but also detects structural deterioration characterised by disorganisation of contractile and cytoskeletal proteins. Genistein was found to improve the overall renal structure.

Elevated circulating lipids may contribute to renal disease progression (27). In contention with this, we observed marked increases in lipid levels in both plasma and kidney of fructose-fed rats. Lipids bind to extracellular matrix molecules and are peroxidised, thereby increasing reactive oxygen species production (28). These processes affect the structure and function of the kidney. Genistein has been shown to be a PPARγ agonist to improve lipid metabolism in murine RAW 264.7 cells and in obese Zucker rats (29). The lipid-lowering effect of genistein observed in the present study could be one of the mechanisms for its renoprotective action.

Hyperglycaemia and angiotensin II are potent inducers of PKC-βII activation (30). Activated PKC-βII translocates to the membrane and triggers the production of endothelin 1, a vasoactive peptide that causes endothelial dysfunction, vascular smooth muscle contraction and proliferation, leading to a rise in BP (31). Fructose-fed rats exhibited hyperglycaemia

References

4. Rajasekar P, Palanisamy N & Anuradha CV (2007) Increase of glucose and inhibition of ACE by genistein could have contributed to the reduction in PKC-βII activation and BP. The BP-lowering effect of genistein has been shown already in stroke-prone spontaneously hypertensive rats (32), ovariectomised hypertensive rats (33), and in spontaneously hypertensive rats (34). Important vascular effects of genistein include an increase in inducible NO synthase activity, inhibition of platelet aggregation and arterial vasorelaxation (35) and prevention of vascular alterations (36).

In conclusion, the inhibitory effect on ACE and PKC-βII activation and increased availability of kinins and NO could be the contributory mechanism for the BP-lowering effect and renoprotection by genistein. It remains to be seen whether the insulin sensitivity effect of genistein may underlie the renoprotective action.

Acknowledgements

The financial support in the form of a Senior Research Fellowship to Dr N. P. from the Indian Council of Medical Research, New Delhi is gratefully acknowledged. A. C. V. designed the study protocol and edited the draft manuscript; N. P. conducted the experiments, analysed the data and wrote the draft of the manuscript. All authors read and approved the final manuscript. The authors declare no conflict of interest.